Floatz logo

ROSOPATAMAB

Prostatic Neoplasms

monoclonal_antibodyPhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

74 Active assets in the Prostatic Neoplasms cohort.

Asset / SponsorPhaseRating
Docetaxel
Merck Sharp & Dohme LLC
Phase 4BBB
Degarelix
Novartis Pharmaceuticals
Phase 4BBB
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 3BBB
Abiraterone Acetate
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
LEUPROLIDE
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

ROSOPATAMAB is also rated in:

prostate cancerDormant
B
Indicative ·
63 / 100
View asset →
Metastatic Prostate CancerDormant
B
Indicative ·
59 / 100
View asset →
gliomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →